Notelovitz M, Kitchens C S, Khan F Y
Center for Climacteric Studies, Inc., Gainesville, FL.
Am J Obstet Gynecol. 1992 Nov;167(5):1255-61. doi: 10.1016/s0002-9378(11)91697-4.
The effects of two triphasic oral contraceptives on coagulation and anticoagulation factors were compared in a 12-month open-label study.
Fifty-two women (mean age 26 years) were enrolled in and completed the study; 20 had been randomly assigned to receive levonorgestrel plus ethinyl estradiol, 24 had been randomly assigned to receive norethindrone plus ethinyl estradiol, and eight surgically sterile women acted as untreated controls. Coagulation and anticoagulation factors were measured at baseline and during the sixth and twelfth months.
Both oral contraceptives produced significant decreases from baseline in prothrombin time and partial thromboplastin time; there were also significant changes in laboratory control times. Factor XII was significantly increased in both oral contraceptive groups after 6 and 12 months. Fibrinogen antigen was significantly increased for norethindrone plus ethinyl estradiol after 6 and 12 months and for levonorgestrel plus ethinyl estradiol after 12 months. Platelet counts were unchanged. There was a significant increase in antithrombin III activity with norethindrone plus ethinyl estradiol at 12 months. Antithrombin III antigen was unchanged with the oral contraceptives; however, significant increases existed for alpha 1-antitrypsin antigen and plasminogen antigen and activity after 6 and 12 months and for alpha 2-macroglobulin antigen after 12 months for both oral contraceptives. alpha 2-Antiplasmin antigen was significantly increased for norethindrone plus ethinyl estradiol at the 12-month evaluation. There were no significant differences between the oral contraceptives for any coagulation or anticoagulation factor, and mean values generally remained within reference ranges.
Levonorgestrel plus ethinyl estradiol and norethindrone plus ethinyl estradiol had equivalent, minimal effects on hemostasis, and changes in coagulation factors appeared to be balanced by changes in anticoagulation factors.
在一项为期12个月的开放标签研究中,比较两种三相口服避孕药对凝血和抗凝因子的影响。
52名女性(平均年龄26岁)参与并完成了该研究;20名被随机分配接受左炔诺孕酮加炔雌醇,24名被随机分配接受炔诺酮加炔雌醇,8名手术绝育的女性作为未治疗对照。在基线以及第六和第十二个月时测量凝血和抗凝因子。
两种口服避孕药均使凝血酶原时间和部分凝血活酶时间较基线显著降低;实验室对照时间也有显著变化。6个月和12个月后,两个口服避孕药组的因子XII均显著升高。6个月和12个月后,炔诺酮加炔雌醇组的纤维蛋白原抗原显著升高,12个月后左炔诺孕酮加炔雌醇组的纤维蛋白原抗原显著升高。血小板计数未改变。12个月时,炔诺酮加炔雌醇使抗凝血酶III活性显著增加。口服避孕药使抗凝血酶III抗原未改变;然而,两种口服避孕药在6个月和12个月后,α1抗胰蛋白酶抗原、纤溶酶原抗原和活性均显著增加,12个月后α2巨球蛋白抗原显著增加。12个月评估时,炔诺酮加炔雌醇组的α2抗纤溶酶抗原显著增加。两种口服避孕药在任何凝血或抗凝因子方面均无显著差异,平均值一般仍在参考范围内。
左炔诺孕酮加炔雌醇和炔诺酮加炔雌醇对止血的影响相当且极小,凝血因子的变化似乎被抗凝因子的变化所平衡。